CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
Privately-held Morphogenesis Inc has agreed to combine with CohBar Inc (NASDAQ:CWBR) in an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
The combined company will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
The combined company is expected to operate under the name "TuHURA Biosciences Inc" and to trade on The Nasdaq Capital Market. The transaction is expected to close in Q3 of 2023.
The lead asset, IFx-Hu2.0, is expected to enter Phase 2/3 registration trial as the first-line treatment for Merkel Cell Carcinoma in early 2024.
Under the terms of the merger agreement, each holder of CohBar common stock will be issued a dividend equal to approximately 3.30 shares of CohBar common stock.
On a pro forma basis, CohBar equity holders are expected to own approximately 15%, and pre-merger Morphogenesis equity holders are expected to own approximately 77%.
CohBar also entered into a $15 million PIPE, with an anticipated cash runway through 2024.
Following the merger, the combined company will be headquartered in Tampa, Florida, and the executive officers are expected to be James Bianco, as CEO, and Dan Dearborn, as CFO.
Price Action: CWBR shares are up 157.60% at $3.99 on the last check Tuesday.
Privately-held Morphogenesis Inc has agreed to combine with CohBar Inc (NASDAQ:CWBR) in an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
私人持有 Morphogen 已同意与 CohBar Inc (NASDAQ: CWBR) 参与一项全股交易，成立了一家结合专业知识和资源推进后期肿瘤学产品线的公司。
The combined company will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
合并后的公司将专注于推进Morphogenesis的两项技术，这些技术旨在克服限制当前免疫疗法治疗癌症有效性的主要障碍。
The combined company is expected to operate under the name "TuHURA Biosciences Inc" and to trade on The Nasdaq Capital Market. The transaction is expected to close in Q3 of 2023.
合并后的公司预计将以 “” 的名义运营。TuHura 生物科学公司“并在纳斯达克资本市场上交易。该交易预计将于2023年第三季度完成。
The lead asset, IFx-Hu2.0, is expected to enter Phase 2/3 registration trial as the first-line treatment for Merkel Cell Carcinoma in early 2024.
主要资产， ifx-HU2.0，预计将于2024年初进入2/3期注册试验，作为默克尔细胞癌的一线治疗方法。
Under the terms of the merger agreement, each holder of CohBar common stock will be issued a dividend equal to approximately 3.30 shares of CohBar common stock.
根据合并协议的条款，CohBar普通股的每位持有人将获得相当于约3.30股CohBar普通股的股息。
On a pro forma basis, CohBar equity holders are expected to own approximately 15%, and pre-merger Morphogenesis equity holders are expected to own approximately 77%.
预计CohBar股权持有人将拥有约15％的股权，合并前的Morphogenesis股权持有人预计将拥有约77％的股权。
CohBar also entered into a $15 million PIPE, with an anticipated cash runway through 2024.
CohBar还签订了1500万美元的PIPE，预计现金流将持续到2024年。
Following the merger, the combined company will be headquartered in Tampa, Florida, and the executive officers are expected to be James Bianco, as CEO, and Dan Dearborn, as CFO.
合并后，合并后的公司将总部设在佛罗里达州坦帕，预计执行官将是担任首席执行官的詹姆斯·比安科和担任首席财务官的丹·迪尔伯恩。
Price Action: CWBR shares are up 157.60% at $3.99 on the last check Tuesday.
价格走势： 在周二的最后一张支票中，CWBR股价上涨了157.60％，至3.99美元。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧